Global Molecular Diagnostics for Cancer Market Report 2021-2025: Markets Forecasts by Cancer Type, Product, and Place with Executive & Consultant Guides and Customization – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Molecular Diagnostics for Cancer 2021-2025: Markets Forecasts by Cancer Type, Product, and Place with Executive & Consultant Guides and Customization” report has been added to ResearchAndMarkets.com’s offering.

A market with fundamental growth factors is impacted by the COVID-19 Pandemic.

This report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2021 United States Medicare Fee Payment Schedules to help understand test pricing in detail. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions.

Molecular Diagnostics for Cancer is positioned to directly benefit from the explosion in genomics knowledge but shifting resources to deal with the COVID emergency may interrupt growth. Learn all about it in this new report. It includes a special segment Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry, and now over 130 companies are profiled.

A range of dynamic trends are pushing market growth and company valuations.

Trends like:

• Personalized medicine;
• Pharmacogenomics;
• Liquid biopsy;
• Emergence of new economies with large markets;
• A greater understanding of the role of genetic material in Disease & Health.

Working against this dynamic market are the forces of the COVID Driven Recession. The latest numbers in this report factor in the different COVID forces and their timing, and their effect on growth.

Exciting technical developments especially in the area of pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage.

In addition to customization work, breakouts for particular segments, assistance and support is included free of charge.

Assistance in providing specific growth and market size estimates for new technology tests is provided. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth.

Key Topics Covered:

1 Molecular Dx Oncology Market – Strategic Situation Analysis with Impact of the COVID-19 Pandemic

2 Guide for Executives, Marketing, Sales and Business Development Staff

3 Guide for Management Consultants and Investment Advisors

4 Introduction and Market Definition

4.1 What is Molecular Diagnostics

4.2 The Diagnostics Revolution

4.3 Market Definition

4.3.1 Revenue Market Size

4.4 Methodology

4.5 U.S. Medical Market and laboratory Testing – Perspective

4.5.1 U.S. Medicare Expenditures for Laboratory Testing

5 Market Overview

5.1 Market Participants

5.2 Market Segments

5.3 Industry Structure

6 Market Trends

6.1 Factors Driving Growth

6.1.1 New Diagnostics Create New Markets

6.1.2 New Roles for Diagnostics

6.1.3 Longevity and Outcomes

6.1.4 Expanding the Pharmaceutical Toolbox

6.1.5 Regulatory Retreat

6.2 Factors Limiting Growth

6.2.1 Falling Prices

6.2.2 Lower Costs

6.2.3 COVID Pandemic

6.2.4 Wellness has a Downside

6.3 Instrumentation and Automation

6.3.1 Instruments Key to Market Share

6.3.2 Bioinformatics Plays a Role

6.4 Diagnostic Technology Development

6.4.1 Next Generation Sequencing

6.4.2 Shifting Role of Diagnostics

6.4.3 Multiplexing and Foundation One

6.4.4 Pharmacogenomics Technology

6.4.5 Whole Genome Sequencing

6.4.6 Gene Editing and Gene Therapy

7 Molecular Diagnostics Recent Developments

7.1 Recent Developments – Importance and How to Use This Section

7.2 Nucleix to Invest in Early-Stage Lung Cancer Dx

7.3 Invitae to Acquire Genosity for $200M

7.4 Bio-Techne Obtains CE Mark for Exosomal Liquid Biopsy Prostate Test

7.5 Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience

7.6 Natera Revenues Grow 35 Percent

7.7 AnchorDx Closes $40M Financing Round

7.8 Exact Sciences Strategy for End-to-End Cancer Testing

7.9 Genomics England: Whole Genome Sequencing for Cancer Patients to Launch

7.10 Singlera Genomics Closes $150M Funding for Cancer Screening

7.11 Biocartis GeneproDx, Endpoint Health Collaborate on Tests for Idylla Platform

7.12 Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test

7.13 Metastatic Cancer Markers Identified in Clinical WGS Study

7.14 Stitch Bio Bets on CRISPR Tech

7.15 Bayer, LifeLabs Launch Free NTRK Genetic Testing Program

7.16 Foundation Medicine Liquid Biopsy Gets FDA Approval for Multiple Companion Dx

7.17 Progress, Challenges in Liquid Biopsy Reimbursement

7.18 Israeli Startup Curesponse Raises $6M

7.19 Coronavirus Pandemic Bites into European Cancer Research

7.20 Veracyte’s Prosigna IDs Patients Likely to Benefit from Aggressive Chemotherapy

7.21 Combining CRISPR and Nanopore Sequencing

7.22 Liquid Biopsy Detects Cancer Early via Cell Clusters

7.23 Roche, Illumina unveil 15-year cancer diagnostic tie-up

7.24 Saga, Servier Sign Liquid Biopsy Services Deal

7.25 Home urine test could revolutionize diagnosis of prostate cancer

7.26 Cancer Gene Tests Cost-Effective for Breast Cancer Patients

7.27 Personal Genome Diagnostics Gets CE Mark for Elio Tissue Assay

7.28 OncoCyte to Buy Cancer Testing Company Razor Genomics

7.29 Blood Test May Eliminate Need for Exploratory Surgery

7.30 NGS Cancer Panel Receives New York State Conditional Approval

7.31 Biocartis Inks Cancer CDx Deal With Bristol-Myers Squibb

8 Profiles of Key MDx Companies: 128 Companies

9 The Global Market for MDx Cancer

9.1 MDx Cancer – Global Market Overview by Country

9.2 Global Market by Cancer Type – Overview

9.3 Global Market by Product Type – Overview

9.4 Global Market by Place – Overview

10. Global Market by Cancer Type

10.1 MDx Breast Cancer

10.2 MDx Colorectal Cancer

10.3 MDx Cervical Cancer

10.4 MDx Lung Cancer

10.5 MDx Prostate

10.6 MDx Melanoma Cancer

10.7 MDx Blood

10.8 MDx Companion Dx Development

11. Global Market by Product Type

11.1 MDx Instruments

11.2 MDx Reagents

11.3 MDx Software and Services

12. Global Market by Place

12.1 MDx Clinical Laboratory

12.2 MDx Pharmaceutical

12.3 MDx Research

13 Cancer Treatment and Trials

13.1 FDA Cancer Drug Approvals by Year

13.2 Clinical Trials Started 2010 to 2016

13.3 Prevalence of Cancer Treatments – 2015

14 Appendices

For more information about this report visit https://www.researchandmarkets.com/r/5fuoi0